Protocols
3 protocol(s) meet the specified criteria
Drug: MDX010
Protocol No.TitleStatus
DFCI17-064/OMNIVOREPhase II study of Optimized Management of NIVOlumab based on REsponse in patients with advanced renal cell carcinoma (OMNIVORE study)Open
LCCC1632Phase II Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal AdenocarcinomaOpen
S1616-CIRBA Phase II Randomized Study of Nivolumab (NSC-732442) With Ipilimumab (NSC-748726) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentOpen